

# Victor Mangas-Sanjuan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3594246/publications.pdf>

Version: 2024-02-01

25  
papers

281  
citations

1162889

8  
h-index

940416

16  
g-index

25  
all docs

25  
docs citations

25  
times ranked

461  
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantitative assessment of the exposure–efficacy relationship of glucocerebrosidase using Markovian elements in Gaucher patients treated with enzyme replacement therapy. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2727-2737.	1.1	0
2	Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis. <i>Pharmaceutics</i> , 2022, 14, 654.	2.0	9
3	Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series. <i>Pharmaceutics</i> , 2022, 14, 1010.	2.0	7
4	Pharmacometric characterization of entero-hepatic circulation processes of orally administered formulations of amiodarone under complex binding kinetics. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 174, 106198.	1.9	1
5	Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 905-915.	1.1	6
6	Current Evidence, Challenges, and Opportunities of Physiologically Based Pharmacokinetic Models of Atorvastatin for Decision Making. <i>Pharmaceutics</i> , 2021, 13, 709.	2.0	9
7	The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives. <i>Pharmaceutics</i> , 2021, 13, 1016.	2.0	9
8	Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors. <i>Cancers</i> , 2021, 13, 5049.	1.7	2
9	Estimators and confidence intervals of $\int_0^{\infty} f(x) dx$ using bootstrap methodology for the comparison of dissolution profiles. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 212, 106449.	2.6	3
10	Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. <i>Drug Metabolism and Personalized Therapy</i> , 2021, .	0.3	0
11	Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2020, 109, 300-308.	0.7	7
12	Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. <i>Pharmaceutics</i> , 2020, 12, 1226.	2.0	4
13	Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease. <i>Pharmaceutics</i> , 2020, 12, 1147.	2.0	0
14	Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice. <i>Pharmaceutics</i> , 2020, 12, 975.	2.0	7
15	Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. <i>Drug Metabolism and Drug Interactions</i> , 2020, 35, .	0.3	1
16	Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration. <i>Pharmaceutics</i> , 2019, 11, 365.	2.0	86
17	Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 117, 193-203.	1.9	5
18	Systematic Modeling and Design Evaluation of Unperturbed Tumor Dynamics in Xenografts. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 366, 96-104.	1.3	9

#	ARTICLE	IF	CITATIONS
19	Population pharmacokinetic model of lithium and drug compliance assessment. <i>European Neuropsychopharmacology</i> , 2016, 26, 1868-1876.	0.3	8
20	Population pharmacokinetic/pharmacodynamic modelling of the effects of axomadol and its O-demethyl metabolite on pupil diameter and nociception in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 92-107.	1.1	6
21	Semimechanistic Cell-Cycle Type-Based Pharmacokinetic/Pharmacodynamic Model of Chemotherapy-Induced Neutropenic Effects of Diflomotecan under Different Dosing Schedules. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 354, 55-64.	1.3	26
22	A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability. <i>European Journal of Medicinal Chemistry</i> , 2014, 83, 366-373.	2.6	22
23	Modified Nonsink Equation for Permeability Estimation in Cell Monolayers: Comparison with Standard Methods. <i>Molecular Pharmaceutics</i> , 2014, 11, 1403-1414.	2.3	18
24	Innovative in Vitro Method To Predict Rate and Extent of Drug Delivery to the Brain across the Blood-Brain Barrier. <i>Molecular Pharmaceutics</i> , 2013, 10, 3822-3831.	2.3	19
25	Semisynthesis, Cytotoxic Activity, and Oral Availability of New Lipophilic 9-Substituted Camptothecin Derivatives. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 651-655.	1.3	17